CXCL12 and colorectal carcinoma: In contrast, in two cohorts of 290 and 306 patients with stage III CRC, high cytoplasmic expression of CXCL12, assessed by in situ hybridization and immunohistochemistry, is associated with a better 5-year event-free survival [120].